Ratings by RBC Capital (Kennan MacKay)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/15/2024 | aTyr Pharma | LIFE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2024 | ADC Therapeutics | ADCT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2023 | ADC Therapeutics | ADCT | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2023 | ADC Therapeutics | ADCT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2023 | ADC Therapeutics | ADCT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2023 | ADC Therapeutics | ADCT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2023 | aTyr Pharma | LIFE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2022 | ADC Therapeutics | ADCT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2022 | aTyr Pharma | LIFE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2022 | ADC Therapeutics | ADCT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2021 | ADC Therapeutics | ADCT | Maintain | Outperform (N/A) |
|
Details | ||
| 10/12/2021 | aTyr Pharma | LIFE | New Coverage | Outperform (N/A) |
9.42 (32.85) |
248.73% | Details | |
| 8/9/2021 | ADC Therapeutics | ADCT | New Coverage | Outperform (N/A) |
24.44 (3.17) |
-87.03% | Details | |
| 8/10/2020 | ProQR Therapeutics N.V. | PRQR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2019 | ProQR Therapeutics N.V. | PRQR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2018 | ProQR Therapeutics N.V. | PRQR | New Coverage | Outperform (N/A) |
17.72 (2.22) |
-87.47% | Details |
